1
|
Chheda Z, Kohanbash G, Sidney J, Okada K, Jahan N, Mueller S, Sette A, Hou Y, Okada H. OS09.4 Identification of a novel H3.3.K27M mutation-derived neoantigen epitope and cloning of H3.3.K27M-specific T-cell receptor for T-cell therapy in gliomas. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
2
|
Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene 2017; 36:3749-3759. [PMID: 28218903 PMCID: PMC5491354 DOI: 10.1038/onc.2017.1] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Revised: 12/20/2016] [Accepted: 12/22/2016] [Indexed: 02/07/2023]
Abstract
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor microenvironment. We confirmed increased tumor-associated macrophages in bevacizumab-resistant glioblastoma patient specimens and two novel glioblastoma xenograft models of bevacizumab resistance. Microarray analysis suggested downregulated macrophage migration inhibitory factor (MIF) to be the most pertinent mediator of increased macrophages. Bevacizumab-resistant patient glioblastomas and both novel xenograft models of resistance had less MIF than bevacizumab-naive tumors, and harbored more M2/protumoral macrophages that specifically localized to the tumor edge. Xenografts expressing MIF-shRNA grew more rapidly with greater angiogenesis and had macrophages localizing to the tumor edge which were more prevalent and proliferative, and displayed M2 polarization, whereas bevacizumab-resistant xenografts transduced to upregulate MIF exhibited the opposite changes. Bone marrow-derived macrophage were polarized to an M2 phenotype in the presence of condition-media derived from bevacizumab-resistant xenograft-derived cells, while recombinant MIF drove M1 polarization. Media from macrophages exposed to bevacizumab-resistant tumor cell conditioned media increased glioma cell proliferation compared with media from macrophages exposed to bevacizumab-responsive tumor cell media, suggesting that macrophage polarization in bevacizumab-resistant xenografts is the source of their aggressive biology and results from a secreted factor. Two mechanisms of bevacizumab-induced MIF reduction were identified: (1) bevacizumab bound MIF and blocked MIF-induced M1 polarization of macrophages; and (2) VEGF increased glioma MIF production in a VEGFR2-dependent manner, suggesting that bevacizumab-induced VEGF depletion would downregulate MIF. Site-directed biopsies revealed enriched MIF and VEGF at the enhancing edge in bevacizumab-naive patients. This MIF enrichment was lost in bevacizumab-resistant glioblastomas, driving a tumor edge M1-to-M2 transition. Thus, bevacizumab resistance is driven by reduced MIF at the tumor edge causing proliferative expansion of M2 macrophages, which in turn promotes tumor growth.
Collapse
Affiliation(s)
- B A Castro
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - P Flanigan
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - A Jahangiri
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - D Hoffman
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - W Chen
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - R Kuang
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - M De Lay
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - G Yagnik
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - J R Wagner
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - S Mascharak
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - M Sidorov
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - S Shrivastav
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - G Kohanbash
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - H Okada
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| | - M K Aghi
- Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, USA
| |
Collapse
|
3
|
Okada H, Butterfield L, Hamilton R, Ahn B, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively M, Chan M, Salazar A, Shaw E, Potter D, Lieberman F. IT-23 * INDUCTION OF ROBUST TYPE-1 CD8+ T-CELL RESPONSES IN WHO GRADE II LOW-GRADE GLIOMA PATIENTS RECEIVING PEPTIDE-BASED VACCINES IN COMBINATION WITH POLY-ICLC. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou258.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Kohanbash G, Straw E, Averick A, Ahn B, Smith-Cohn M, Ohkuri T, Kosaka A, Okada H. IT-17 * ONO-AE3-208 INHIBITS MYELOID-DERIVED SUPPRESSOR CELLS AND GLIOMA GROWTH. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou258.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Smith-Cohn M, Kohanbash G, Muthuswamy R, Ohkuri T, Kosaka A, Amankulor N, Engh J, Potter D, Kalinski P, Okada H. IT-33 * USE OF IFN-ALPHA AND POLY-ICLC AS CHEMOKINE MODULATORS FOR IMMUNOTHERAPY IN GLIOMAS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou258.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Potter DM, Shaw EG, Lieberman FS. ROBUST INDUCTION OF TYPE-1 CD8+ T-CELL RESPONSES IN WHO GRADE II LOW-GRADE GLIOMA PATIENTS RECEIVING PEPTIDE-BASED VACCINES IN COMBINATION WITH POLY-ICLC. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou208.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, Wang Y, Cahill DP, Levine NB, Prabhu SS, Rao G, Sawaya R, Heimberger AB, de Vrij J, Kwappenberg KMC, Maas SLN, Kleijn A, Lamfers ML, Dirven CMF, Schilham MW, Broekman MLD, Garcia-Velasco A, del Barco S, Alvarez R, Fuentes R, Marruecos J, Hernando O, Rubio C, Menendez J, Brunet J, Hidalgo M, Jung TY, Kim YH, Jung S, Jang WY, Moon KS, Kim IY, Lee MC, Lee JJ, Kohanbash G, McKaveney K, Sakaki M, Mintz A, Ohlfest J, Bondy M, Fujita M, Okada H, Liu Y, Ohno M, Okada H, Raychaudhuri B, Vogelbaum MA, Sabin KZ, Lebert D, Thibado V, Rovin R, Lawrence J, Winn R, Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M, Belcaid Z, Phallen JA, Zeng J, See AP, Albesiano E, Durham NM, Tyler B, Brem H, Pardoll DM, Drake C, Lim M, Sippel TR, White J, Russel R, Waziri A, Kohanbash G, Ishikawa E, Fujita M, Ohno M, Liu Y, Sakaki M, Ikeura M, Scheurer M, Bondy M, Okada H, Yi HQ, Duan YL, Yang CQ, Seo KS, Bohach G, Fortunato E, Luo MH. IMMUNOLOGY RESEARCH. Neuro Oncol 2011. [DOI: 10.1093/neuonc/nor150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Wu A, Wei J, Kong LY, Wang Y, Priebe W, Sawaya R, Heimberger AB, Wei J, Wu A, Kong LY, Wang Y, Priebe W, Heimberger A, Kong LY, Doucette T, Wei J, Priebe W, Sawaya R, Yang J, Rao G, Heimberger A, Shimato S, Meier LM, Castelli M, Canoll P, Asslaber M, Bruce JN, Anderson DE, Anderson RC, Mahlum EW, Jenkins RB, Kohanbash G, Mintz AH, McKaveney K, McDonald HA, Ohlfest JR, Okada H, Fujita M, Zhang L, Liu W, Alizadeh D, Zhao D, Farrukh O, Badie B, Raychaudhuri B, Pellegatta S, Cantini G, Pisati F, Cuppini L, Finocchiaro G, Albesiano E, Han JE, See A, Jackson C, Lim M, Nag K, White J, Sippel T, Klaassen M, Tsvankin V, Waziri A, Mittal S, Zitron IM, Kupsky WJ, Alkonyi B, Sood S, Juhasz C, Zitron IM, Juhasz C, Mittal S. Immunology Research. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Fujita M, Kohanbash G, McDonald HA, Delamarre L, Decker SA, Ohlfest JR, Okada H, Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS, Olin MR, Andersen BM, Grogan PT, Hunt M, Popescu FE, Xiong ZL, Seiler C, Forster CL, SantaCruz KS, Chen W, Blazar BR, Ohlfest JR, Hu J, Wheeler CJ, Phuphanich S, Rudnick J, Nuno M, Serrano N, Dantis J, Richardson J, Mazer M, Wang HQ, Chu R, Black KL, Yu J, Li YM, Vallera DA, Hall WA, Rudnick JD, Wheeler CJ, Phuphanich S, Chu RM, Mazer M, Wang H, Serrano N, Nuno M, Richardson J, Hu J, Black KL, Yu JS, Yang I, Han S, Tihan T, Wrensch M, Parsa AT, Li YM, Vallera DA, Hall WA, Andersen BM, Hunt MA, Gallardo JL, Seiler C, Pluhar GE, Ohlfest JR, Brown CE, Starr R, Martinez C, Bading J, Ressler JA, Badie B, Jensen MC, Glick RP, Ksendzovsky A, Zengou R, Polak P, Simonini V, Lichtor T, Feinstein D, Chow KK, Ahmed N, Salsman VS, Kew Y, Powell S, Grossman R, Heslop HE, Gottschalk S, Barnett FH, Marchetti V, Wang M, Johnson A, Scheppke L, Jacobson R, Nemerow G, Friedlander M, Ahmed N, Salsman V, Kew Y, Leen AM, Bollard CM, Powell S, Grossman R, Rooney C, Heslop HE, Gottschalk S, New PZ, Bollard CM, Salvoldo B, Heslop H. Immunotherapy. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|